Caplin Point Laboratories LimitedNSE: CAPLIPOINT

Press Release Mar 08 2023

· Issued by Caplin Point Laboratories Limited

Filed with NSE ·

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated March 08, 2023, titled "Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Thiamine Hydrochloride Injection USP".

View Attachment

6ix hasn’t read this filing yet.

Caplin Point Laboratories Limited on 6ix

Earlier from Caplin Point Laboratories

Later from Caplin Point Laboratories

All Caplin Point Laboratories news releases